FORT LEE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and...
LAWRENCEVILLE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated...
NEEDHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
PRINCETON, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing...
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Aug. 01, 2023 (GLOBE...
LOS ANGELES, July 31, 2023 (GLOBE NEWSWIRE) -- Solve GNE announced today that it has entered into a sponsored research...
WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Acquisition aims to strengthen BioNTech’s pioneering position in the field of AI-powered drug discovery, design and developmentInstaDeep to operate as...
Media Release Late-stage & registrational trial progress: TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational...
Media Release Mini Oral presentation will include data from TACTI-002 Phase II trial evaluating chemotherapy-free IO combination of efti plus...
Media Release SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 Lausanne, Switzerland, July 28, 2023 – AC Immune SA...
Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study...
Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second IndicationCompany Selects Refractory Advanced Genitourinary Malignancies including Renal...
Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27,...
55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate...
BOSTON, July 24, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and...
MAINZ, Germany, July 24, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial...
Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary...